Pharmafile Logo
Pharmafocus logo
Advanced Search

atopic dermatitis

Showing 15 posts of 21 posts found.

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …

News

UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy

February 24, 2021
Research and Development atopic dermatitis, eczema

Researchers at the University of California San Diego School of Medicine have identified a universal strain of bacteria derived from …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

News
sanofi

Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis

June 22, 2020
Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma

China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …

News
stock-incyte-01-shutter

Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis

April 7, 2020
Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib

Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …

News

Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis

April 3, 2020
Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …

News
shutterstock_212432119

Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

October 31, 2019
Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …

News

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019
Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …

News
dupixentpackage

Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis

August 7, 2019
Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …

News

Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis

May 16, 2019
Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …

News
lilly_building_with_american_flag_web

Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

February 5, 2019
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …

News

Atopic dermatitis market set to almost triple in value over next 10 years

December 12, 2018
Research and Development atopic dermatitis, eczema, global data, markets, money

The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData. The market …

News

Sanofi’s Dupixent improves symptoms for adolescent atopic dermatitis patients

September 17, 2018
Research and Development, Sales and Marketing Dupixent, EADV 2018, Sanofi, atopic dermatitis, pharma

Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic …

News

Realm Therapeutics shares halved after failure of Phase 2 study

August 15, 2018
Research and Development London, Shares, atopic dermatitis, phase 2, stock market

Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …

News

NICE backs Sanofi’s new treatment for atopic dermatitis

June 22, 2018
Medical Communications, Sales and Marketing England, NICE, Sanofi, UK, atopic dermatitis, pharma

NICE has published a positive Final Appraisal Determination FAD recommending dupilumab, in combination with topical corticosteroids, for use on the …

News

Latest content

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023

Eli Lilly to acquire POINT Biopharma

October 4, 2023

Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment

October 3, 2023

WHO recommends new vaccine for prevention of malaria in children

October 3, 2023

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023